139 related articles for article (PubMed ID: 8819504)
1. Labeling of A2A adenosine receptors in human platelets by use of the new nonxanthine antagonist radioligand [3H]SCH 58261.
Dionisotti S; Ferrara S; Molta C; Zocchi C; Ongini E
J Pharmacol Exp Ther; 1996 Sep; 278(3):1209-14. PubMed ID: 8819504
[TBL] [Abstract][Full Text] [Related]
2. Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261.
Dionisotti S; Ongini E; Zocchi C; Kull B; Arslan G; Fredholm BB
Br J Pharmacol; 1997 Jun; 121(3):353-60. PubMed ID: 9179373
[TBL] [Abstract][Full Text] [Related]
3. Characterization of A2A adenosine receptors in human lymphocyte membranes by [3H]-SCH 58261 binding.
Varani K; Gessi S; Dalpiaz A; Ongini E; Borea PA
Br J Pharmacol; 1997 Sep; 122(2):386-92. PubMed ID: 9313951
[TBL] [Abstract][Full Text] [Related]
4. [3H]-SCH 58261 labelling of functional A2A adenosine receptors in human neutrophil membranes.
Varani K; Gessi S; Dionisotti S; Ongini E; Borea PA
Br J Pharmacol; 1998 Apr; 123(8):1723-31. PubMed ID: 9605581
[TBL] [Abstract][Full Text] [Related]
5. The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist.
Zocchi C; Ongini E; Conti A; Monopoli A; Negretti A; Baraldi PG; Dionisotti S
J Pharmacol Exp Ther; 1996 Feb; 276(2):398-404. PubMed ID: 8632302
[TBL] [Abstract][Full Text] [Related]
6. Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes.
Zocchi C; Ongini E; Ferrara S; Baraldi PG; Dionisotti S
Br J Pharmacol; 1996 Apr; 117(7):1381-6. PubMed ID: 8730729
[TBL] [Abstract][Full Text] [Related]
7. [(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors.
Varani K; Merighi S; Gessi S; Klotz KN; Leung E; Baraldi PG; Cacciari B; Romagnoli R; Spalluto G; Borea PA
Mol Pharmacol; 2000 May; 57(5):968-75. PubMed ID: 10779381
[TBL] [Abstract][Full Text] [Related]
8. Binding of [3H]KF17837S, a selective adenosine A2 receptor antagonist, to rat brain membranes.
Nonaka H; Mori A; Ichimura M; Shindou T; Yanagawa K; Shimada J; Kase H
Mol Pharmacol; 1994 Nov; 46(5):817-22. PubMed ID: 7969067
[TBL] [Abstract][Full Text] [Related]
9. Characterization of two affinity states of adenosine A2a receptors with a new radioligand, 2-[2-(4-amino-3-[125I]iodophenyl)ethylamino]adenosine.
Luthin DR; Olsson RA; Thompson RD; Sawmiller DR; Linden J
Mol Pharmacol; 1995 Feb; 47(2):307-13. PubMed ID: 7870039
[TBL] [Abstract][Full Text] [Related]
10. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A(2A) adenosine antagonists.
Baraldi PG; Cacciari B; Spalluto G; Pineda de las Infantas y Villatoro MJ; Zocchi C; Dionisotti S; Ongini E
J Med Chem; 1996 Mar; 39(5):1164-71. PubMed ID: 8676354
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.
Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA
J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A adenosine receptor antagonists.
Baraldi PG; Cacciari B; Spalluto G; Bergonzoni M; Dionisotti S; Ongini E; Varani K; Borea PA
J Med Chem; 1998 Jun; 41(12):2126-33. PubMed ID: 9622554
[TBL] [Abstract][Full Text] [Related]
13. Binding of the novel nonxanthine A2A adenosine receptor antagonist [3H]SCH58261 to coronary artery membranes.
Belardinelli L; Shryock JC; Ruble J; Monopoli A; Dionisotti S; Ongini E; Dennis DM; Baker SP
Circ Res; 1996 Dec; 79(6):1153-60. PubMed ID: 8943953
[TBL] [Abstract][Full Text] [Related]
14. Kinetic and functional properties of [3H]ZM241385, a high affinity antagonist for adenosine A2A receptors.
Uustare A; Vonk A; Terasmaa A; Fuxe K; Rinken A
Life Sci; 2005 Feb; 76(13):1513-26. PubMed ID: 15680315
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line.
Merighi S; Varani K; Gessi S; Cattabriga E; Iannotta V; Ulouglu C; Leung E; Borea PA
Br J Pharmacol; 2001 Nov; 134(6):1215-26. PubMed ID: 11704641
[TBL] [Abstract][Full Text] [Related]
16. Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors.
Kull B; Arslan G; Nilsson C; Owman C; Lorenzen A; Schwabe U; Fredholm BB
Biochem Pharmacol; 1999 Jan; 57(1):65-75. PubMed ID: 9920286
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological and biochemical characterization of purified A2a adenosine receptors in human platelet membranes by [3H]-CGS 21680 binding.
Varani K; Gessi S; Dalpiaz A; Borea PA
Br J Pharmacol; 1996 Apr; 117(8):1693-701. PubMed ID: 8732278
[TBL] [Abstract][Full Text] [Related]
18. G protein coupling of CGS 21680 binding sites in the rat hippocampus and cortex is different from that of adenosine A1 and striatal A2A receptors.
Cunha RA; Constantino MD; Ribeiro JA
Naunyn Schmiedebergs Arch Pharmacol; 1999 Apr; 359(4):295-302. PubMed ID: 10344528
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular pharmacology of the A2A adenosine receptor antagonist, SCH 58261, in the rat.
Monopoli A; Casati C; Lozza G; Forlani A; Ongini E
J Pharmacol Exp Ther; 1998 Apr; 285(1):9-15. PubMed ID: 9535988
[TBL] [Abstract][Full Text] [Related]
20. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats.
Pinna A; Fenu S; Morelli M
Synapse; 2001 Mar; 39(3):233-8. PubMed ID: 11284438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
